Related references
Note: Only part of the references are listed.Neutrophils mediate antibody-induced antitumor effects in mice
Marcello Albanesi et al.
BLOOD (2013)
Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model
Emily L. Williams et al.
CLINICAL CANCER RESEARCH (2013)
Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein
Caroline Staff et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism
Suresh Veeramani et al.
BLOOD (2011)
Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
Kory L. Alderson et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Padmanee Sharma et al.
NATURE REVIEWS CANCER (2011)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
From research to regulated: challenges in transferring methods
Ferdousi Chowdhury et al.
BIOANALYSIS (2009)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
Tom van Meerten et al.
CLINICAL CANCER RESEARCH (2006)
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
NKV Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice
Y Zeng et al.
MOLECULAR IMMUNOLOGY (2005)
Of mice and not men: Differences between mouse and human immunology
J Mestas et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
